Clinical trials: Metastatic Castration-resistant Prostate Cancer (mCRPC)
- Condition Metastatic Castration-resistant Prostate Cancer (mCRPC)
- Funder type Industry (pharma, biotech, devices)
Cancer, Metastatic Castration-resistant Prostate Cancer
Study of INKmune in Patients With mCRPC (CaRe Prostate)
This is an open-label, phase I/IIa dose escalation and expansion study of INKmune in men with mCRPC. INKmune is administered to patients intravenously over three doses, at least one-week apart.
- Conditions
- Cancer, Metastatic Castration-resistant Prostate Cancer, mCRPC
- Trial name
- CaRe (NCT06056791)
- Testing
- INKmune
- Where
- 8 sites in United States
- Volunteers
- 12 people
- Sponsor
- Inmune Bio, Inc.
Prostate Cancer
A Trial of CTT1403 for Metastatic Castration Resistant Prostate Cancer
The purpose of this study is to find the highest dose level of study drug, CTT1403, that can be safely administered to patients with metastatic castration resistant prostate cancer (mCRPC).
- Trial name
- NCT03822871
- Testing
- CTT1403, CTT1057, 68Ga-PSMA-11
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Cancer Targeted Technology
Metastatic Castration-Resistant Prostate Cancer
Study to Evaluate Exicorilant (CORT125281) in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer
This study consists of a dose escalation study with an expansion phase to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD), and preliminary efficacy of exicorilant (CORT125281) in combination…
- Trial name
- NCT03437941
- Testing
- Exicorilant, Enzalutamide
- Where
- 9 sites in United States, United Kingdom
- Volunteers
- 39 people
- Sponsor
- Corcept Therapeutics
Metastatic Castration-resistant Prostate Cancer
Post Marketing Study on Pluvicto in Korea
Post marketing study on Pluvicto in Korea
- Trial name
- NCT06514521
- Testing
- Lutetium vipivotide tetraxetan
- Where
- 12 sites in South Korea
- Volunteers
- 278 people
- Sponsor
- Novartis Pharmaceuticals
Metastatic Castration-resistant Prostate Cancer, Metastatic Castration-sensitive Prostate Cancer
TAVT-45 (Abiraterone Acetate) Granules in Patients With Prostate Cancer
The purpose of this study is to investigate the safety and efficacy of a new formulation of an existing drug product called TAVT-45 in patients with metastatic prostate cancer.
- Conditions
- Metastatic Castration-resistant Prostate Cancer, Metastatic Castration-sensitive Prostate Cancer, Metastatic Prostate Cancer
- Trial name
- NCT04887506
- Testing
- TAVT-45, Zytiga, Prednisone
- Where
- 42 sites in United States, France and 6 more
- Volunteers
- 107 people
- Sponsor
- Tavanta Therapeutics
Metastatic Castrate Resistant Prostate Cancer (mCRPC), Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
The Safety and Tolerability of GT0918 in Subjects With mHSPC and mCRPC
This was a multiple-center, open-label, randomized, daily dose, two-sequence, expanded/phase II study in subjects with mHSPC or mCRPC who progressed after either abiraterone or enzalutamide treatment.
- Trial name
- NCT03899467
- Testing
- GT0918
- Where
- 10 sites in United States
- Volunteers
- 61 people
- Sponsor
- Suzhou Kintor Pharmaceutical Inc,
Metastatic Castrate-Resistant Prostate Cancer, mCRPC (Metastatic Castration-resistant Prostate Cancer)
Study of XNW5004 Tablet in Combination With Enzalutamide in Subjects With Metastatic Castration-Resistant Prostate Cancer
In this phase Ib/II study, participants with metastatic castration-resistant prostate cancer (mCRPC) who failed prior novel hormone therapy will be treated with XNW5004 in combination with enzalutamide.
- Trial name
- NCT06702995
- Testing
- XNW5004, enzalutamide
- Where
- 2 sites in China
- Volunteers
- 307 people
- Sponsor
- Evopoint Biosciences Inc.
Metastatic Castration-resistant Prostate Cancer
Phase 0/1 Study of 212Pb-NG001 in mCRPC
The purpose of this study is to evaluate the imaging feasibility and safety of 212Pb-NG001.
- Trial name
- NCT05725070
- Testing
- 212Pb-NG001
- Where
- Norway
- Volunteers
- 3 people
- Sponsor
- ARTBIO Inc.
Prostate Cancer, mCRPC
A Phase 3 Study of [177Lu]Ludotadipep for Metastatic Castration-Resistant Prostate Cancer
Primary Efficacy Endpoint Radiographic Progression-Free Survival (rPFS): rPFS is defined as the time from randomization to radiographic disease progression (PD), as assessed by Blinded Independent Central Review (BICR) according…
- Trial name
- NCT07853209
- Testing
- [177-Lu]Ludotadipep, Best supportive care/standard of care (BSC/SOC) alone
- Where
- 8 sites in South Korea
- Volunteers
- 114 people
- Sponsor
- FutureChem
Castration-Resistant Prostatic Cancer, Metastatic Disease
Safety and Targeting of Anti-hk2 Antibody in mCRPC
This is an imaging trial, to develop h11B6 as a therapeutic radiopharmaceutical for men with mCRPC. This imaging study will be conducted to confirm the safety and estimate the mass amount of antibody h11B6, and confirm in vivo…
- Trial name
- NCT04116164
- Testing
- 111In-DOTA-h11B6
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- SpectronRX
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T
A multicenter, open-label, prospective study to investigate immune boost response changes in patients with metastatic castrate-resistant prostate cancer (mCRPC).
- Trial name
- ProvONE (NCT06134232)
- Testing
- Sipuleucel-T Injection
- Where
- 31 sites in United States
- Volunteers
- 400 people
- Sponsor
- Dendreon
Prostate Cancer Metastatic Castration-Resistant
A Study of KMV002 in Patients With mAPMR Prostate Cancer
This is a first-in-human (FIH) open-label, multicenter, dose-escalation and dose-expansion Phase I study of KMV002 in metastatic androgen pathway modulation-resistant (mAPMR) prostate cancer patients.
- Trial name
- NCT07866300
- Testing
- KMV002
- Where
- 2 sites in Australia
- Volunteers
- 24 people
- Sponsor
- Chimivac INC
Prostate Cancer Metastatic
EMD 525797 in Subjects With Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer
The primary objective of the trial is to evaluate the clinical anti-tumor activity of EMD 525797 administered as 1-hour intravenous infusion every 3 weeks in terms of progression free survival (PFS) time in subjects with…
- Trial name
- PERSEUS (NCT01360840)
- Testing
- EMD 525797, Standard of Care (SoC)
- Where
- 71 sites in United States, Australia and 10 more
- Volunteers
- 180 people
- Sponsor
- EMD Serono
Prostate Cancer
QLC5508 in Participants With Metastatic Prostate Cancer
This is a randomized, open-label, active-controlled, multicenter Phase III trial evaluating QLC5508 versus docetaxel in participants with metastatic castration-resistant prostate cancer (mCRPC) who have progressed after prior…
- Trial name
- NCT07632690
- Testing
- QLC5508, Docetaxel
- Volunteers
- 700 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Prostate Cancer Metastatic
Early Switch From First-Line Docetaxel/Prednisone to Cabazitaxel/Prednisone and the Opposite Sequence, Exploring Molecular Markers in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Docetaxel and cabazitaxel are cancer chemotherapy agents of the taxane drug class. The purpose of this study is to explore the benefit, for treatment of metastatic castration-resistant prostate cancer (mCRPC), of a regimen in…
- Trial name
- TAXYNERGY (NCT01718353)
- Testing
- DOCETAXEL (XRP6976), CABAZITAXEL (XRP6258), Prednisone
- Where
- 19 sites in United States, Canada
- Volunteers
- 63 people
- Sponsor
- Sanofi
Prostatic Neoplasms
A Prospective Compliance Registry for Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
The primary purpose of this study is to determine the rate of compliance to abiraterone acetate and prednisone (AA + P) treatment in Colombian Castration-resistant metastatic prostate cancer (mCRPC) participants experiencing…
- Trial name
- TOGETHER (NCT02905201)
- Sponsor
- Janssen Research & Development, LLC
Prostatic Neoplasms
177Lu-PSMA-617 vs. Androgen Receptor-Directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer
The purpose of this study is to determine whether 177Lu-PSMA-617 improves the Radiographic progression-free survival (rPFS) or Overall Survival (OS) compared to a change in Androgen receptor-directed therapy (ARDT) in metastatic…
- Trial name
- PSMAfore (NCT04689828)
- Testing
- 177Lu-PSMA-617, 68Ga-PSMA-11, ARDT
- Where
- 72 sites in United States, Austria and 12 more
- Volunteers
- 469 people
- Sponsor
- Novartis Pharmaceuticals
Prostate Cancer
EPI-7386 in Combination with Enzalutamide Compared with Enzalutamide Alone in Subjects with MCRPC
This is a Phase 1/2 study of EPI-7386 orally administered in combination with enzalutamide in subjects with mCRPC. Phase 1 of the study will be a single-arm dose escalation study of EPI-7386 in combination with a fixed dose of…
- Trial name
- NCT05075577
- Testing
- Enzalutamide, EPI-7386 with Enzalutamide
- Where
- 24 sites in United States, Australia and 1 more
- Volunteers
- 77 people
- Sponsor
- ESSA Pharmaceuticals
Metastatic Castration-resistant Prostate Cancer
Autologous Immune Cell Therapy in Combination With LHRH-a in Patients With mCRPC
Study of autologous immune cell therapy in combination with the luteinizing hormone releasing hormone agonists (LHRH-a) in patients with metastatic castration-resistant prostate cancer
- Trial name
- NCT03085966
- Testing
- autologous immune cell therapy
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shanghai AbelZeta Ltd.
Metastatic Castration-resistant Prostate Cancer, MCRPC
A Study to Investigate Efficacy and Safety of Different Dose Regimen of Oral Cabazitaxel Tablet in Adult Participants with Prostate Cancer
A total of 75 participants will be enrolled in the study, with 25 participants allocated per intervention group. In Group 1, participant will take 50 mg cabazitaxel every week for 6 cycles (3 doses per cycle), 10 mg prednisone…
- Trial name
- NCT06890832
- Testing
- 50 mg cabazitaxel, 100 mg cabazitaxel, 200 mg cabazitaxel
- Volunteers
- 75 people
- Sponsor
- Jina Pharmaceuticals Inc.